Synvista Therapeutics
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$2.59
-0.0
-7.66
$55K
9
Synvista Therapeutics, Inc. is a biotechnology company, which engages in the development of diagnostic tests and pharmaceutical drugs for the treatment of diabetes. The company is headquartered in Montvale, New Jersey and currently employs 9 full-time employees. The firm's lead drug candidate, alagebrium chloride or alagebrium, is an advanced glycation end-product crosslink breaker being developed for diastolic heart failure (DHF). Synvista is also managing a discovery and development program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx). One of the Company’s GPx mimetics, ALT-2074, is in Phase II clinical trials.
Synvista Therapeutics, Inc. is a biotechnology company, which engages in the development of diagnostic tests and pharmaceutical drugs for the treatment of diabetes. The company is headquartered in Montvale, New Jersey and currently employs 9 full-time employees. The firm's lead drug candidate, alagebrium chloride or alagebrium, is an advanced glycation end-product crosslink breaker being developed for diastolic heart failure (DHF). Synvista is also managing a discovery and development program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx). One of the Company’s GPx mimetics, ALT-2074, is in Phase II clinical trials.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.